Clinical Trials Logo

Solid Cancers clinical trials

View clinical trials related to Solid Cancers.

Filter by:

NCT ID: NCT00876109 Completed - Solid Cancers Clinical Trials

A Study of GDC-0941 in Participants With Locally Advanced or Metastatic Solid Tumors for Which Standard Therapy Either Does Not Exist or Has Proven Ineffective or Intolerable

Start date: October 2007
Phase: Phase 1
Study type: Interventional

This is an open-label, multicenter, Phase I, dose-escalation study to assess the safety, tolerability, and pharmacokinetics of orally administered GDC-0941 administered once daily (QD) and twice daily (BID) in the treatment of advanced or metastatic solid tumors.

NCT ID: NCT00747734 Completed - Solid Cancers Clinical Trials

A Study of MNRP1685A in Patients With Locally Advanced or Metastatic Solid Tumors

Start date: September 2008
Phase: Phase 1
Study type: Interventional

This is a Phase I, first-in-human, open-label, dose-escalation study of MNRP1685A administered by IV infusion every 3 weeks in patients with locally advanced or metastatic solid tumors for whom standard therapy either does not exist or has proven to be ineffective or intolerable. This study will be conducted at up to three study centers in the United States.

NCT ID: NCT00096941 Completed - Solid Cancers Clinical Trials

A Study to Evaluate Subjects Treated With rhuMab 2C4 (Pertuzumab) in a Previous Genentech Phase II Cancer Study

Start date: May 2005
Phase: Phase 2
Study type: Interventional

This is a multicenter, open label extension study. Subjects who have completed treatment in the parent study of pertuzumab, either alone or with a combination agent, and who received at least one dose of pertuzumab in the parent study are eligible for inclusion in this trial if they are continuing to receive clinical benefit.